Hester Biosciences Profit & Loss Annual

BSE: - | NSE: - | ISIN: - | Sector: -

2,049.90 -19.60 (-0.95%)Updated : 16 Jun 2026

Interim Data

Annual Data

Fiscal Period	2026	2025	2024	2023
Period End Date	Mar 26	Mar 25	Mar 24	Mar 23
Total Operating Expense	261.89	265.88	266.28	236.18
Other Net	9.68	0.40	5.73	11.78
Diluted Weighted Average Shares	0.82	0.85	0.85	0.85
Depreciation/ Amortization	18.88	16.80	17.17	20.70
Operating Income	70.71	45.22	38.26	29.91
Net Income	55.64	27.49	18.89	26.63
Income Availableto Com Excl Extra Ord	55.64	27.49	18.89	26.63
Other Operating Expenses Total	101.32	2.96	3.17	3.74
Net Income Before Taxes	75.84	39.57	31.95	40.15
Minority Interest	-1.85	-1.34	-2.28	-1.41
Net Income After Taxes	57.48	28.83	21.17	28.04
Income Availableto Com Incl Extra Ord	55.64	27.49	18.89	26.63
Costof Revenue Total	81.96	113.04	122.21	95.56
Gross Profit	250.64	198.06	182.34	170.53
Interest Inc( Exp) Net- Non- Op Total	-4.56	-5.56	-12.07	-1.56
Unusual Expense( Income)	-2.94	0.00	-1.18	-
Diluted Net Income	55.64	27.49	18.89	26.63
DPS- Common Stock Primary Issue	11.00	7.00	6.00	8.00
Provisionfor Income Taxes	18.35	10.75	10.79	12.12
period Type	-	-	-	-
Net Income Before Extra Items	55.64	27.49	18.89	26.63
Total Revenue	332.60	311.10	304.55	266.09
period Length	12.00	12.00	12.00	12.00
Revenue	332.60	311.10	304.55	266.09
Selling/ General/ Admin Expenses Total	62.67	133.08	124.91	116.18
Diluted Normalized EPS	64.87	32.73	21.27	31.29
Diluted EPS Excluding Extra Ord Items	67.57	32.31	22.20	31.30
Gain( Loss)on Saleof Assets	-	-0.49	0.03	0.02